5 results on '"Wang, Ruiying"'
Search Results
2. Research on the application effect of cognitive stimulation therapy in patients with Alzheimer's disease based on expert consultation and semistructured interviews
- Author
-
Li, Shuzhen, Ge, Hongyan, Wu, Wei, Wang, Ruiying, and Zamzaliza Abdul, Mulud
- Subjects
Cognition ,Alzheimer Disease ,Intelligence ,Quality of Life ,Humans ,Referral and Consultation - Abstract
The awareness and utilization of psychological therapies for Alzheimer's disease have increased significantly in recent years. Limitations on the utilization of pharmacological therapy for Alzheimer's disease in China have corresponded with this surge in greater studies in the field. For individuals who have Alzheimer's disease, cognitive stimulation therapy (CST) is a quick self-help that is founded on the theories of quality and cognitive functioning. People with Alzheimer's disease often participate in cognitive behavioral programs; however, their expense has never been studied. Being part of a meta-analysis, we analyze the application effectiveness of a CST program that is based on recent research for Alzheimer's disease patients. A CST group therapy was given to 91 Alzheimer's patients, who resided in healthcare settings or the general public, multiple times per week for 8 weeks; the other 70 people with Alzheimer's disease got a medical therapy. Costs were computed, and resource utilization was tracked for 8 weeks both before and after the therapy. It was determined by a value study. In the value study, cognition and quality of life were the major and tertiary outcomes, respectively. Contours of cost-effectiveness and acceptance were drawn. It was driven based on expert consultation and semistructured interviews. In Alzheimer's disease, CST improves intelligence and standard of living, and there was no difference in implementation expenditures between the categories. Regarding both outcome metrics, there is a significant chance that CST seems to be more expensive than conventional therapy within realistic expectations. The efficacy of CST for Alzheimer's patients is superior to conventional treatment, and it could be the greater value. The outcomes contrast well with pharmacological studies for Alzheimer's. Many people with Alzheimer's disease may benefit significantly from CST groups.
- Published
- 2022
3. Clinical features and three-year prognosis of AECOPD patients with different levels of blood eosinophils
- Author
-
Wang Ruiying, null Zhaoyun, and Xu Jianying
- Subjects
Pulmonary and Respiratory Medicine ,Inflammation ,Dust ,Critical Care and Intensive Care Medicine ,Prognosis ,Anti-Bacterial Agents ,Eosinophils ,Pulmonary Disease, Chronic Obstructive ,Leukocyte Count ,Eosinophilia ,Disease Progression ,Humans ,Cardiology and Cardiovascular Medicine ,Retrospective Studies - Abstract
Eosinophils are thought to be associated with the frequency and severity of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); however, the role of eosinophilic inflammation in AECOPD is still incompletely understood.To investigate the relationship between different levels of blood eosinophils and clinical features, including comorbidities, therapy, and prognosis, and to further explore the optimal eosinophilic cutoff.We retrospectively collected and analyzed medical data, laboratory findings, chest CT images, treatment, and three-year follow-up data from 984 AECOPD patients with different blood eosinophil (EOS) levels: EOS%2%, ≥2%; EOS%3%, ≥3%; eosinophil counts100 cells/L, ≥100 cells/L.The prevalence of eosinophilia was 36.48% of EOS≥2% (359 cases), 22.87% of EOS≥3% (225 cases), and 48.48% with eosinophil counts≥100 cells/µl (477 cases). EOS was associated with comorbidities, including pulmonary heart disease, arrhythmia (atrial fibrillation), laboratory testing and clinical treatment, including respiratory failure, airway limitation, infectious inflammation, rate of antibiotic use, systemic glucocorticoids, and three mortality rates. The ROC curve showed that the indicators of AUC≥0.5 included chest CT imaging (emphysema 1.8% or ≥100/µl, bronchitis, 1.7% or ≥100/µl), osteoporosis (2.4% or ≥140/µl), mental illness 6.1% (or ≥400/µl), dust exposure (2.2% or ≥240/µl) and ex-smoker (1.3% or ≥100/µl).The relatively higher EOS group (≥2% or ≥100/µl) was associated with fewer complications, mild airflow limitation, a tendency of noninfectious inflammation, and lower 3-year mortality. Eosinophils can not only guide clinical treatment but also be an indicator of predicting clinical outcome and prognosis in AECOPD patients.
- Published
- 2021
4. Vaccines for human fungal diseases: close but still a long way to go
- Author
-
Oliveira, Lorena V. N., Wang, Ruiying, Specht, Charles A., and Levitz, Stuart M.
- Subjects
0301 basic medicine ,Pharmacology ,Fungal vaccine ,Aspergillus ,biology ,030106 microbiology ,Immunology ,Cryptococcus ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Diseases ,Review Article ,RC581-607 ,biology.organism_classification ,Virology ,03 medical and health sciences ,Nucleic Acid Vaccines ,030104 developmental biology ,Infectious Diseases ,Immune system ,Human disease ,Antigen ,Human use ,Pharmacology (medical) ,Immunologic diseases. Allergy ,RC254-282 - Abstract
Despite the substantial global burden of human fungal infections, there are no approved fungal vaccines to protect at risk individuals. Here, we review the progress that has been made and the challenges that lie ahead in the quest towards efficacious fungal vaccines. In mouse studies, protection has been achieved with vaccines directed against fungal pathogens, including species of Candida, Cryptococcus, and Aspergillus, that most commonly cause life-threatening human disease. Encouraging results have been obtained with vaccines composed of live-attenuated and killed fungi, crude extracts, recombinant subunit formulations, and nucleic acid vaccines. Novel adjuvants that instruct the immune system to mount the types of protective responses needed to fight mycotic infections are under development. Candidate vaccines include those that target common antigens expressed on multiple genera of fungi thereby protecting against a broad range of mycoses. Encouragingly, three vaccines have reached human clinical trials. Still, formidable obstacles must be overcome before we will have fungal vaccines licensed for human use.
- Published
- 2021
5. SCALE-UP FOR ALKANE ISOMERIZATION
- Author
-
Li Shi, Wang Ruiying, Guoxiong Huang, and Cheng-Lie Li
- Subjects
Alkane ,chemistry.chemical_classification ,General Chemical Engineering ,General Chemistry ,Mordenite ,Catalysis ,Hexane ,Pentane ,chemistry.chemical_compound ,Pilot plant ,chemistry ,Organic chemistry ,Microreactor ,Isomerization - Abstract
Pentane and hexane hydroisomerization were studied in detail in a microreactor system. This information was very useful for scale-up of catalyst production capaity arid isomerization reactors. In our work, properties of catalysts produced in different amounts were reproduceable and hydroisomerization results in the microrector, lab scale reactor and pilot plant were compatible. It was shown a easy way has been paved to develope a new alkane isomerization catalyst.
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.